Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578671 | 0.82 | KMT2A (0.36) | KMT2AMEN1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL5578492 | 0.80 | HSD11B1 (0.39) | KMT2AMEN1ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL2316904 | 0.77 | SIGMAR1 (0.47) | KMT2AMEN1ALDH1A1KDM4ETSHR | |
| SCHEMBL3708454 | 0.76 | CYP1A2 (0.40) | KMT2AMEN1ALDH1A1TSHRLMNA | |
| SCHEMBL2853081 | 0.75 | CHRM1 (0.41) | ALDH1A1KDM4ETSHRLMNACYP3A4 | |
| SCHEMBL592971 | 0.74 | SLC6A4 (0.61) | — | |
| SCHEMBL217536 | 0.74 | CYP1A2 (0.42) | KMT2AMEN1TSHRLMNACYP3A4 | |
| SCHEMBL17100732 | 0.72 | NPC1 (0.40) | ALDH1A1SMN1; SMN2TSHRLMNA | |
| SCHEMBL15961230 | 0.71 | SIGMAR1 (0.52) | KMT2AALDH1A1KDM4ESMN1; SMN2TSHR | |
| SCHEMBL4084298 | 0.71 | MAPK1 (0.46) | KMT2AMEN1ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758884-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | KMT2A 3354/4885MEN1 2423/4885ALDH1A1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.